ATM and neoplasm: We also observed decreasing CellSearch circulating tumor cell (CTC) counts on treatment in 6 of these patients, with 3 of these patients also having a relatively long rPFS despite the absence of BRCA gene loss (22 months in a patient with FANCI alteration; 13 months in a patient with ATM alteration; 8 months in a patient with CDK12 alteration).